Daniel Albert, MD: Telemedicine Challenges for Rheumatologists During COVID-19

Video

Three key issues with using the technology over in-person visits.

The use of telemedicine during coronavirus disease 2019 (COVID-19) has allowed rheumatologists to continue caring for patients virtually. But the technology comes with many challenges.

The primary concern is a lack of a physical exam, Daniel Albert, MD, of Dartmouth-Hitchcock, said in a recent interview with HCPLive®. Rheumatologists often rely on a physical examination to get a better look at the whole patient.

“It’s a very difficult transition for providers to care for patients without a physical exam,” he said.

There are workarounds, however, but they require ingenuity. For example, patients often show Albert how they walk, how they use their upper extremities for activities, and physical exam maneuvers can be done similarly to how they would be done in person, but they have to use a visual rather than sensory input. Sometimes rheumatologists can elicit tender points on an individual if they are asked to put pressure on certain areas.

Other concerns exist, such as patients who are simply not suited for a virtual appointment, whether it be because they have a visual impairment or less cognitive ability than is required to conduct such an interview virtually. Sometimes diseases are just too complex and there are too many comorbidities, or the patient has too severe of a disease.

Lastly, it’s important for patients to buy into the idea of virtual encounters. If patients are uncomfortable, you have to give them the opportunity to be seen in the clinic.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.